A Study to Evaluate Camrelizumab in Combination With Nb-Paclitaxel in Patients With Advanced or Metastatic NSCLC

NCT04167774 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

62

Enrollment

OTHER

Sponsor class

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG: Camrelizumab
DRUG: nb-Paclitaxel

Sponsor

Sun Yat-sen University

Collaborators

[object Object]